<DOC>
	<DOCNO>NCT00725751</DOCNO>
	<brief_summary>Although injection drug user represent majority new exist case infection hepatitis C virus ( HCV ) , many lack access treatment concern adherence , effectiveness , reinfection . On basis small grow body evidence show injection drug user undergo treatment HCV infection successfully , 2002 NIH Consensus Statement Hepatitis C recommend substance user treat HCV infection case-by-case basis . In study , patient receive pegylated interferon alfa-2b ( PegIFN-2b ) ribavirin accord European labeling ; one cohort participant also receive substitution therapy ( opioid medicine long-lasting effect [ methadone + buprenorphine ] morphine ) .</brief_summary>
	<brief_title>Treatment Chronic Hepatitis C With Pegylated Interferon Ribavirin Participants With/Without Substitution Therapy ( P05255 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Adult patient hepatitis C According product ' European labeling</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>